MXCT · Maxcyte, Inc. · Investor Relations
Press releases and events scraped from the company’s investor relations website. Past events open our own call or event page when we host one; otherwise listings link to the original source.
Upcoming events
| Date | Event | Type |
|---|---|---|
| 2026-10-30 00:00 UTC | ESGCT 2026 | Event |
| 2026-11-10 21:30 UTC | Q3 FY2026 Earnings conference call (announced in 8-K) | Earnings call |
Recent news
| Date | Headline |
|---|---|
| 2026-10-14 |
MaxCyte Reports Preliminary Third Quarter 2026 Revenue and Raises Full Year 2026 Revenue Guidance
MaxCyte will host its third quarter 2026 earnings conference call on November 10, 2026 ROCKVILLE, Md., Oct. 14, 2026 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (NASDAQ: MXCT), a leading cell-engineering company providing enabling platform technologies to advance the discovery, development and |
| 2026-09-23 |
MaxCyte Appoints Sidharth Kapileshwar as Chief Corporate Development Officer
ROCKVILLE, Md., Sept. 23, 2026 (GLOBE NEWSWIRE) -- MaxCyte, Inc. (Nasdaq: MXCT), a leading cell engineering company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell therapeutics, today announced that it has appointed |
| 2026-09-11 |
MaxCyte Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
ROCKVILLE, Md., Sept. 11, 2026 (GLOBE NEWSWIRE) -- MaxCyte, Inc. (Nasdaq: MXCT), a leading cell-engineering focused company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell therapeutics, reported today that the Compensation |
| 2026-08-19 |
MaxCyte launches CHANGE-seq-BE™ and ONE-seq-BE™ to strengthen off-target assessment for genome editing therapies
ROCKVILLE, Md., Aug. 19, 2026 (GLOBE NEWSWIRE) -- MaxCyte, Inc. (NASDAQ: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell therapeutics, today announced the launch of the |
| 2026-08-12 |
MaxCyte Reports Second Quarter 2026 Financial Results
Reports total revenue of $7.3 million for the second quarter of 2026, including $6.5 million of core revenue and $0.8 million of SPL Program-related revenue Reiterates Full Year 2026 Guidance Repurchased approximately $5.5 million of common stock to date under the Company’s $10 million share |
| 2026-07-21 |
MaxCyte® Announces Multi-Platform Technology License Partnership with Genentech® to Advance Cell Therapy Development
Technology License Partnership provides Genentech access to MaxCyte’s portfolio of platform technologies across research, development, and manufacturing workflows ROCKVILLE, Md., July 21, 2026 (GLOBE NEWSWIRE) -- MaxCyte, Inc. (Nasdaq: MXCT), a leading cell-engineering company providing enabling |
| 2026-07-15 |
MaxCyte to Report Second Quarter 2026 Financial Results on August 12, 2026
ROCKVILLE, Md., July 15, 2026 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (NASDAQ: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell therapeutics, today announced that it will |
| 2026-06-23 |
VectorBuilder Partners with MaxCyte® to Advance Clinical-Grade Cell Engineering
The next-generation platform integrates VectorBuilder’s regulatory-compliant gene delivery technology with MaxCyte’s clinically validated electroporation platform to enable robust, scalable, and reliable clinical-grade cell engineering. Chicago, IL & Rockville, MD – June 23, 2026 – VectorBuilder, a |
| 2026-05-12 |
MaxCyte Reports First Quarter 2026 Financial Results and Reiterates Full Year 2026 Guidance
First quarter 2026 total revenue of $9.7 million, including $6.2 million of core revenue and $3.4 million of SPL Program-related revenue Reiterates 2026 revenue guidance of $30-32 million; with Core revenue of $25-27 million and Strategic Platform License (SPL) Program-related of $5 million |
| 2026-04-29 |
MaxCyte to Report First Quarter 2026 Financial Results on May 12, 2026
ROCKVILLE, Md., April 29, 2026 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (NASDAQ: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell therapeutics, today announced that it will |
| 2026-03-31 |
MaxCyte Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
ROCKVILLE, Md., March 31, 2026 (GLOBE NEWSWIRE) -- MaxCyte, Inc. (Nasdaq: MXCT), a leading cell-engineering focused company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell therapeutics, reported today that Compensation |
| 2026-03-24 |
MaxCyte Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Full Year 2026 Guidance
Fourth quarter 2025 total revenue of $7.3 million at the top of the range of previous preliminary announcement Full year 2025 revenue of $33.0 million, at the top of the range of previous preliminary announcement Total cash, cash equivalents and investments were $155.6 million as of December 31, |
| 2026-03-23 |
MaxCyte Appoints Parmeet Ahuja as Chief Financial Officer
ROCKVILLE, Md., March 23, 2026 (GLOBE NEWSWIRE) -- MaxCyte, Inc. (Nasdaq: MXCT), a leading cell-engineering focused company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell therapeutics, today announced that it has |
Past events
Source: https://investors.maxcyte.com/